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Abstract
Autologous chondrocyte implantation (ACI) has been used to treat cartilage defects for >20 years, with promising clinical
outcomes. Here, we report two first-in-man cases (patient A and B) treated with combined autologous chondrocyte and bone
marrow mesenchymal stromal cell implantation (CACAMI), with 8-year follow up. Two patients with International Cartilage
Repair Society (ICRS) grade III–IV cartilage lesions underwent a co-implantation of autologous chondrocytes and bone
marrow-derived mesenchymal stromal cells (BM-MSCs) between February 2008 and October 2009. In brief, chondrocytes
and BM-MSCs were separately isolated and culture-expanded in a good manufacturing practice laboratory for a period of
2–4 weeks. Cells were then implanted in combination into cartilage defects and patients were clinically evaluated pre-
operatively and postoperatively, using the self-reported Lysholm knee score and magnetic resonance imaging (MRI). Post-
operative Lysholm scores were compared with the Oswestry risk of knee arthroplasty (ORKA) scores. Patient A also had a
second-look arthroscopy, at which time a biopsy of the repair site was taken. Both patients demonstrated a significant long-
term improvement in knee function, with postoperative Lysholm scores being consistently higher than ORKA predictions.
The most recent Lysholm scores, 8 years after surgery were 100/100 (Patient A) and 88/100 (Patient B), where 100 represents
a fully functioning knee joint. Bone marrow lesion (BML) volume was shown to decrease on postoperative MRIs in both
patients. Cartilage defect area increased in patient A, but declined initially for patient B, slightly increasing again 2 years after
treatment. The repair site biopsy taken from patient A at 14 months postoperatively, demonstrated a thin layer of fibro-
cartilage covering the treated defect site. The use of a combination of cultured autologous chondrocytes and BM-MSCs
appears to confer long-term benefit in this two-patient case study. Improvements in knee function perhaps relate to the
observed reduction in the size of the BML.
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Introduction
Autologous chondrocyte implantation (ACI) is a cell-based
therapeutic strategy which has been used for more than
20 years for the treatment of cartilage defects1. ACI has
shown promising clinical outcomes in terms of pain relief
and in delaying joint degeneration2,3. ACI has also recently
been approved by the National Institute for Health and Care
Excellence (NICE TA 477). This historic decision is antici-
pated to have a profound impact, as ACI is now considered
to be the ‘gold standard’ to treat chondral defects (greater
than 2 cm in diameter and not previously treated with
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microfracture). However, there are still some unsolved chal-
lenges, such as possible donor-site morbidity4,5, and variable
structural cartilage regeneration as noted using imaging and
histological analyses6.
Bone marrow-derived mesenchymal stromal cells (BM-
MSCs) have chondrogenic potential which can be enhanced
by co-culture with chondrocytes7,8. Orozco et al. have con-
firmed the safety and feasibility of using autologous BM-
MSCs to treat cartilage defects9. They reported 65% to 78%
improvement in knee pain and knee function after implanta-
tion, demonstrating improved outcomes compared with con-
ventional treatment (e.g. acupuncture, placebo, debridement,
lavage), at 12 months postoperatively, with maintained
improvement up to 2 years10.
BM-MSCs were initially proposed to maintain their mul-
tipotent capacity and contribute directly to repair cartilage
formation and engraftment, with MSCs persisting in multi-
ple tissues for as long as 13 months after transplantation11.
However, another study showed that BM-MSCs migrate to
the site of damaged cartilage and are stimulated by local
inflammatory cytokines or hypoxia to produce large quanti-
ties of growth factors which promote tissue regeneration12.
Additionally, MSCs have been found to enhance tissue
repair by secreting soluble factors which suppress the
inflammatory response and stimulate endogenous stem cell
proliferation and differentiation13.
Combining cultured autologous chondrocytes and BM-
MSCs may be of benefit for cartilage regeneration but to our
knowledge this has not been reported on in a clinical study.
In this first-in-man study we report two cases of such treat-
ment, hereafter referred to as combined autologous chondro-
cyte and MSC implantation (CACAMI), with 8 years of
clinical outcome data.
Materials and Methods
Patient Information
Two male patients are described in the study: Patient A (70
years of age, body mass index (BMI) 25.25) and Patient B
(65 years of age, BMI 22.09) both presented with unilateral
knee osteoarthritis (OA) and full thickness cartilage loss on
their medial femoral condyles (International Cartilage
Repair Society (ICRS) grade III–IV). Patient A, a keen run-
ner, started to feel right knee pain at 61 years of age and was
unable to run at all 9 years later, at the time of treatment. His
baseline X-ray showed the complete loss of the medial joint
space with sclerosis present in the subchondral bone of the
tibia and femur. Patient B began to feel pain in his right knee,
without any proximate cause, at the age of 62. At 3 years
later, at the time of treatment, he was unable to walk more
than a quarter of a mile and could not mobilize around a golf
course without the use of a buggy. Both patients were offered
knee replacement surgeries but, as keen sportsmen, each
wished to avoid arthroplasty, hence they were offered
CACAMI. Patient demographic and treatment information,
which is distinct for each case, is summarized in Table 1.
Both patients were fully informed that although cultured
chondrocytes and BM-MSCs had each been used individu-
ally for many years to treat chondral defects, the combina-
tion had not yet been used clinically. The process was
explained in full and the patients provided informed consent.
Each patient consented to an ethically approved project
(REACT 09/H1203/90, approved by South Staffordshire
Local Research Ethics Committee, UK).
Surgical Procedures and Cell Therapy Delivery
The two-stage procedure was performed in both cases by the
same surgeon. The first stage was a diagnostic arthroscopy,
at which time macroscopically healthy cartilage was har-
vested from a low load-bearing area of the femoral trochlea
in both patients. Additionally, 20 ml of bone marrow was
aspirated from the iliac crest.
Isolated chondrocytes and BM-MSCs were expanded in
monolayer culture as described previously14,15. Briefly, the
cartilage biopsy was dissected into 2 mm3 pieces and
digested in collagenase type II (245 IU/mg dry weight,
Worthington, USA) for 16 hours at 37C. Chondrocytes
were plated out in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 supplement with 20% autologous serum,
50 mg/ml ascorbic acid (Sigma Aldrich, Poole, UK) and
antibiotics at a seeding density of 5  103 cells/cm2. Cells
were passaged at 70% confluence and reseeded in culture
medium containing 10% autologous serum. Then chondro-
cytes were passaged a further 1 or 2 times and prepared for
Table 1. Patient Demographic and Treatment Information.
Case
Defects (number
and location) Previous procedures
Preoperative
Lysholm score Operative notes (at cell implantation)
A 1 Patella
1 MTP
1 MFC
None 50 4 weeks after tissue harvest, intra-articular injection
of chondrocytes and BM-MSCs with hyaluronan.
B 1 Patella
1 MTP
1 MFC
Debridement 12 months previously
(absent meniscus noted)
75 2 weeks after tissue harvest, traditional ACI with
a BM-MSC-seeded Actifit® meniscal transplant.
ACI: autologous chondrocyte implantation; BM-MSC: bone marrow-derived mesenchymal stromal cells; MFC: medial femoral condyle; MTP: medial tibial
plateau.
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implantation within 4 weeks. To culture BM-MSCs, mono-
nuclear cells were isolated by density gradient centrifuge
(LymphoprepTM, Fresenius Kabi Norge AS, Norway) were
seeded at a density of 20 million cells per 75 cm2 flask in
DMEM/F12 supplement with 15% autologous serum and
antibiotics. BM-MSCs were passaged at 70% confluence and
cultured in medium with 10% autologous serum. The cells
were subcultured for a further 1–2 passages and implanted
within 4 weeks. Cartilage and bone marrow aspiration har-
vest and final cell yields are summarized in Table 2. Chon-
drocytes and BM-MSCs were released for implantation upon
conformance to expect morphological characteristics and if
cell populations were at least 90% viable, as assessed by
trypan blue exclusion (as described in detail in a published
current clinical trial)16.
Patient A underwent a second arthroscopic procedure, in
which the chondral defect on the medial femoral condyle
was debrided. After this, combined autologous chondrocytes
and BM-MSCs were injected into the joint, followed by
hyaluronic acid (60 mg in 3 ml Durolane; Fig. 1). Patient
B’s second stage surgery involved a parapatellar arthrotomy,
in which the defect edges were cut vertically using surgical
blades. A porcine collagen type I/III membrane (Chondro-
gide, Geistlich Biomaterials, Wolhusen, Switzerland) was
sutured to the surrounding healthy cartilage using 6.0 Vicryl
(Ethicon Leeds, UK). The edges of the patch were sealed to
the edges of the defect with fibrin glue (Tisseel, ImmunoAG,
Vienna, Austria). Finally, a suspension of cultured chondro-
cytes was injected underneath the patch, after which a BM-
MSC-seeded medial Actifit® polyurethane meniscal scaffold
(Orteq Sports Medicine, London, UK) was transplanted.
Clinical Assessments
Each patient was evaluated preoperatively and postopera-
tively up to 8 years, using a modified Lysholm score17.
Actual postoperative scores were compared with scores pre-
dicted using the Oswestry risk of knee arthroplasty (ORKA)
score. The ORKA score2 is a web-based application that uses
baseline information about the patient’s age and sex, loca-
tion of and the number of cartilage defects and baseline knee
function score to predict a patient’s risk of needing knee
arthroplasty (Fig. 2). Postoperative magnetic resonance ima-
ging (MRI) scans at 2, 6, 13, 39, 49, 60 and 86 months for
Patient A and at 5, 17, 25 and 52 months for Patient B were
undertaken to assess the cartilage and bone using two scoring
systems. The magnetic resonance observation of cartilage
repair tissue (MOCART) score, which evaluates cartilage
repair tissue18 and the whole-organ magnetic resonance ima-
ging score (WORMS). WORMS provides whole-organ eva-
luation of the total knee joint by assessing not only the
cartilage, but also various other structures, including the
menisci, ligaments, subchondral bone and bone marrow19.
For each patient, longitudinal postoperative MOCART and
WORMS scores were evaluated by a radiologist with signif-
icant experience in OA and ACI (Table 3). A higher
Table 2. Bone Marrow and Cartilage Cell Isolation and Growth Kinetic Information.
Case
Bone marrow Cartilage
Culture time (days)
Volume
(ml)
Cell number
Weight
(mg)
Cell number
Initial MNC Implanted BM-MSCs Initial Implanted
A 20 4106 8 106 301 4.9105 4106 28
B 20 3106 6 106 286 4.0105 4106 14
BM-MSC: bone marrow-derived mesenchymal stromal cell; MNC: mononuclear cell.
Fig. 1. Arthroscopic images of the medial femoral condyle in
Patient A. (A) A full-thickness cartilage defect was observed at the
time of cell implantation (red dashed-line). (B) Following the deb-
ridement of the lesion, the cultured chondrocytes and MSCs were
injected into the synovial cavity, in combination with hyaluronan.
MSC: mesenchymal stromal cell.
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MOCART score indicates better cartilage repair, whereas a
lower WORMS value indicates a better preserved joint.
Bone marrow lesions (BMLs) were also assessed and mea-
sured as described previously20 and depicted in Fig. 3.
A second-look arthroscopy was performed in Patient A,
14 months after cell therapy, in which a biopsy of repair
cartilage was taken. The sample was snap-frozen in liquid
nitrogen-cooled hexane and sectioned at 7 mm thickness
onto poly-L-lysine coated glass slides. Sections were
stained with hematoxylin and eosin or toluidine blue to
assess general morphology and proteoglycan content,
respectively. Collagen fiber orientation was examined
under polarized light to differentiate between hyaline car-
tilage and fibrocartilage.
Results
Both patients reported improvements, as measured by pain
reduction, within a year of treatment. No complications from
surgery were noted in either patient. Further improvements
continued up until the time of reporting this study (8-year
follow up) and both patients currently remain physically
active without joint replacement, with Lysholm scores of
100 and 88, for patients A and B respectively (Fig. 2). Patient
A returned to running competitively and has recently taken
up swimming. Patient B continues to compete in cycling
races. His main residual symptom at final review is pain that
develops after driving for more than 1 hour.
Patient A showed progressive enlargement of chondral
defects identified on MRI (Fig. 4A), whereas in Patient B
Fig. 2. A comparison of the longitudinal, postoperative actual
Lysholm score and ORKA prediction score. (A) For Patient A, the
actual score gradually increased to 100, surpassing predicted scores
at each time point. (B) For Patient B, the actual score increased
initially to 100, after which the score decreased to 83, matching
ORKA predictions. Subsequently the actual score then increased
again to 88 at the 5-year time point.
ORKA: Oswestry risk of knee arthroplasty.
Table 3. A Summary of the MRI Scores (WORMS and MOCART)
for Patient A and B.
Patient Months Post-op WORMS (0–332) MOCART (0–100)
A 3 133.5 10
14 112 15
61 124 15
B 5 138 75
17 138 60
52 143.5 60
MOCART: magnetic resonance observation of cartilage repair tissue; MRI:
magnetic resonance imaging; WORMS: whole-organ magnetic resonance
imaging score.
Fig. 3. Measurement of the bone marrow lesion volume on MRI
within the medial tibial plateau of patient A. (A) In the coronal
image, the LM dimension (2.3 cm) and SI dimension (1.5 cm) of the
lesion are measured. (B) In the sagittal image the AP dimension of
the same lesion (1.8 cm) is measured.
AP: anterior-posterior; LM: lateral-medial; MRI: magnetic reso-
nance imaging; SI: superior-inferior.
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the defect area declined initially and increased slightly
2 years after implantation (Fig. 4B). In both patients, the size
of BMLs decreased gradually over time in the tibia as well as
the femur. This was especially evident in Patient B, in whom
more than 80% of the BMLs disappeared (Fig. 5A and B).
MOCART and WORMS scores at three different times
are shown in Table 3. For patient A, the WORMS score
fluctuated over time, while the MOCART only margin-
ally improved from 10 to 15. However, for patient B both
scores consistently deteriorated over time, but MOCART
scores (from 75 to 50) were consistently higher than for
Patient A. Additionally, there was no evidence demon-
strating the presence of the scaffold or new meniscal
tissue in postoperative MRI at 5-month follow up and
beyond for patient B.
At second-look arthroscopy for Patient A, 12 months after
surgery, the treated defect on the medial femoral condyle
was observed to be generally well healed with firm repair
tissue on probing, but with a slightly irregular surface. In
contrast, the tibial plateau repair cartilage appeared soft but
smooth. Histologically, a thin layer of fibrocartilage had
formed in the treated defect on the medial femoral condyle,
measuring 0.5 mm in depth where previously the bone had
been exposed.
Discussion
Our previous case report showed the feasibility of combining
ACI with bone graft to treat a major osteochondral defect in
the hip following trauma21. Combining cultured autologous
chondrocytes and BM-MSCs may be of benefit for cartilage
regeneration but to our knowledge has not been reported
previously in a clinical study. We believe this is the first
case report to demonstrate the safety of using combined
autologous chondrocytes and autologous BM-MSCs to treat
cartilage defects. Clinical symptoms improved dramatically
in both patients treated, up to 8 years follow up. We have
previously identified six important predictive factors (age,
sex, defect number and location, previous surgery, preopera-
tive Lysholm score) in ACI-treated patients, which appear to
influence progression to arthroplasty. The combination of
these six parameters was used to construct an ORKA index
to predict the survival of ACI repair2. In this study, both
patients were over 60 years old and had multiple defects
including patella sites, as well as low preoperative Lysholm
Fig. 4. Cartilage defect size measured fromMRIs for Patients A and
B. (A) The area of the cartilage defects gradually increased over
time for Patient A, whereas the size of cartilage defects decreased
for the first 2 years, but increased again thereafter for Patient B (B).
MRI: magnetic resonance imaging.
Fig. 5. BML size measured from MRIs for Patients A and B. (A) The
BMLs continuously decreased in volume, particularly on the tibial
side for Patient A, whereas the BMLs continuously decreased in
volume both on the tibial and femoral sides for Patient B (B).
BML: bone marrow lesion; MRI: magnetic resonance imaging.
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scores, which when using the ORKA assessment indicates a
poor prognosis. However, both patients’ postoperative
Lysholm scores were consistently higher than ORKA
predictions.
The patient-reported Lysholm score may have some lim-
itations associated with its subjectivity. However, our group
and many others consistently use such a subjective patient-
reported outcome as the primary outcome of clinical
trials16,17,22. The reason being that ultimately, how the
patient feels about their knee function, is the most important
clinical observation and metric of treatment success/failure.
Moreover, several studies have shown that there is no corre-
lation between subjective functional outcome such as
Lysholm score and objective measures such as histological
analyses23,24. We have taken measures to help to reduce the
limitations associated with the use of subjective scores,
including for comparison objective measures (clinical ima-
ging scores) and where possible, histological observations.
In addition, we have not relied upon a single Lysholm out-
come, but include several, longitudinal postoperative scores
for each patient which helps to add further confidence.
The second-look arthroscopy and histological assess-
ments showed that the cartilage defects in Patient A were
repaired with a thin layer of fibrocartilage which was not
noted at 1-year follow-up MRI. Patient B’s cartilage defect
sizes were reduced in the early postoperative assessments in
contrast to tissue to Patient A, in which the defect sizes
increased progressively after treatment. This difference
could be attributed to the use of a patch covering the treat-
ment site in Patient A, or to the difference in cell delivery
method. Patient B’s injected BM-MSCs may have migrated
out of the implanted Actifit® scaffold and exerted their
effects elsewhere within the joint. However, no firm conclu-
sions regarding which cell delivery method represents the
better cartilage repair technique can be drawn.
The size of the BMLs in both patients gradually decreased
over time. BML is a technical term to describe the high-signal
intensity pathological change on MRI25. There are multiple
studies demonstrating the positive correlations between
BMLs and the pathogenesis of knee pain26–28. A large pro-
spective cohort study of 358 patients in Korea showed the
prevalence of BMLs in patients with knee OA was 80.3%.
After adjusting for age, sex and BMI, the presence and sever-
ity of BMLs in the medial compartment were significantly
associated with knee pain27. Zhang et al. reported similar
results, showing that the changing size of BMLs was related
to knee pain fluctuations, and the reduction of BMLs could
lower the risk of frequent knee pain29. Although Sower et al.
demonstrated a poor relationship between the presence of
knee pain and the presence of BMLs on MRI30, a systematic
review on 22 studies showed moderate evidence that BMLs
were associated with knee OA pain31.
In a recent systematic review, the clinical outcome of 347
patients who had undergone Actifit® (meniscal) implanta-
tion without cells was evaluated and graft failure occurred in
9.9% of patients at a mean follow up of 40 months32. For
Patient B, treated with CACAMI and Actifit®, postoperative
MRI at 5-month follow up demonstrated no obvious signal
for the presence of the scaffold or new meniscal tissue, indi-
cating possible resorption of the scaffold. In comparison,
Gelber et al. reported that patients with no chondral injuries
showed an improved size and morphology of transplanted
Actifit® scaffolds using MRI at a median follow up of
39 months (range 25–63)33.
In conclusion, we believe these two case studies suggest
that combination of cultured autologous chondrocytes and
BM-MSCs appears to confer improved symptoms at least in
these two patients. However, despite the improvement in
clinical outcome scores, physical joint failure as assessed
by MRI is progressing in both patients. Whether this might
have progressed with advancing age at a greater rate had the
cells not been implanted, will only be resolved in a full
clinical trial. In summary, these findings support the hypoth-
esis that autologous BM-MSCs stimulate a beneficial host
response, reducing pain, perhaps by influencing the sub-
chondral bone and reducing the size of BMLs.
Authors’ Note
Please note that Professor James Richardson (last author) was the
initial corresponding author who dedicated his life to the advance-
ment of cell therapy for cartilage repair. Professor Richardson sud-
denly passed away last year. These two cases were performed by
him 10 years ago and we believe these to be the first examples of
such a combined treatment. Here we report good clinical outcomes
for these first-in-man cases in long-term follow up.
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